Jiangsu Nhwa Pharmaceutical Co., Ltd.

Jiangsu Nhwa Pharmaceutical Co., Ltd. is a Chinese pharmaceutical manufacturing company founded in 1978 and listed on the Shenzhen Stock Exchange in 2008 under the stock code 002262. The company integrates research and development, manufacturing, and marketing, specializing in the production of central nervous system (CNS) drugs. Nhwa is recognized as a nationally designated manufacturing base for psychotropic drugs and has achieved various certifications and accolades in the pharmaceutical industry. Nhwa's primary focus is on CNS drug products, including anesthesiology, psychiatry, and neurology, and it has developed a comprehensive range of products in these areas. The company operates three large-scale GMP production bases and has significant production capacity for active pharmaceutical ingredients (APIs) and finished products. Additionally, Nhwa is engaged in the development of cardiovascular drugs, including a new anti-hypertension drug, Iptakalim. The company emphasizes technological innovation and collaborates with academic institutions to enhance its research capabilities, maintaining a strong presence in the specialized CNS market through its established sales network.

1. Company’s development strategy focuses on the market of central nerve system (CNS) drugs, and NHWA is the nationally designated manufacturing base for narcotic and psychotropic drugs withintegrated product line, which constitutes its unique core competitiveness. 2. The projects under developmentcover main kinds of CNS drugs. The R&D centre is in the domestic leading position in chemical synthesis and the development of new dosage forms including sustained release preparations, injectable emulsions, orally disintegrating tablets and dispersible tablets etc. Multiple inventionpatents have been submitted and authorized. 3. Board of directors pays high attention to the research and development and supportsa lot in funds and talents. Nhwa has possessed a quite powerful team of researchers and expertswith ability on the development of brandnew drugs. Nhwa has established an integratedplatform for the study of innovative psychotropic drugs and analgesic drugs. 4. Nhwais highly recognized in pharmaceutical industry with the establishment of characteristic sale network in specialized CNS market after continuously and frequently holding academic activities about anesthesiology, psychiatry and neurology. 5. Nhwa possesses all the manufacturing processes including the synthesis of API and the production of finished products. The extension of production and business makes profit marginhigher.